Free Trial
NASDAQ:ASMB

Assembly Biosciences (ASMB) Stock Price, News & Analysis

Assembly Biosciences logo
$14.18 +2.74 (+23.95%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$14.08 -0.11 (-0.74%)
As of 05/2/2025 06:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Assembly Biosciences Stock (NASDAQ:ASMB)

Key Stats

Today's Range
$11.81
$14.26
50-Day Range
$8.26
$14.18
52-Week Range
$7.75
$19.93
Volume
83,750 shs
Average Volume
26,105 shs
Market Capitalization
$108.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.00
Consensus Rating
Moderate Buy

Company Overview

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Assembly Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
73rd Percentile Overall Score

ASMB MarketRank™: 

Assembly Biosciences scored higher than 73% of companies evaluated by MarketBeat, and ranked 202nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Assembly Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Assembly Biosciences has only been the subject of 2 research reports in the past 90 days.

  • Read more about Assembly Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Assembly Biosciences are expected to decrease in the coming year, from ($6.87) to ($7.64) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Assembly Biosciences is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Assembly Biosciences is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Assembly Biosciences has a P/B Ratio of 1.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Assembly Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    0.47% of the float of Assembly Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Assembly Biosciences has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Assembly Biosciences has recently increased by 8.77%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Assembly Biosciences does not currently pay a dividend.

  • Dividend Growth

    Assembly Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.47% of the float of Assembly Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Assembly Biosciences has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Assembly Biosciences has recently increased by 8.77%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Assembly Biosciences has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Assembly Biosciences this week, compared to 6 articles on an average week.
  • MarketBeat Follows

    3 people have added Assembly Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Assembly Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,726.00 in company stock.

  • Percentage Held by Insiders

    Only 5.10% of the stock of Assembly Biosciences is held by insiders.

  • Percentage Held by Institutions

    Only 19.92% of the stock of Assembly Biosciences is held by institutions.

  • Read more about Assembly Biosciences' insider trading history.
Receive ASMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Assembly Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ASMB Stock News Headlines

Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.As head of the Department of Government Efficiency (DOGE) under President Trump, Musk is exposing just how bad things are...
Assembly Biosciences initiated with a Buy at Guggenheim
Assembly Biosciences files $250M mixed securities shelf
See More Headlines

ASMB Stock Analysis - Frequently Asked Questions

Assembly Biosciences' stock was trading at $15.78 at the beginning of the year. Since then, ASMB stock has decreased by 10.1% and is now trading at $14.18.
View the best growth stocks for 2025 here
.

Assembly Biosciences, Inc. (NASDAQ:ASMB) announced its quarterly earnings results on Thursday, March, 20th. The biopharmaceutical company reported ($1.57) EPS for the quarter, topping analysts' consensus estimates of ($1.75) by $0.18. The biopharmaceutical company earned $7.36 million during the quarter, compared to the consensus estimate of $7.05 million. Assembly Biosciences had a negative trailing twelve-month return on equity of 121.46% and a negative net margin of 144.05%.

Assembly Biosciences shares reverse split before market open on Monday, February 12th 2024. The 1-12 reverse split was announced on Monday, February 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Top institutional shareholders of Assembly Biosciences include Palumbo Wealth Management LLC (0.24%). Insiders that own company stock include Alexander Schornstein, John G Mchutchison, Jason A Okazaki, Nicole S White, Michael P Samar, William E Iv Delaney, Jeanette M Bjorkquist and Michael Houghton.
View institutional ownership trends
.

Shares of ASMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Assembly Biosciences investors own include Waste Connections (WCN), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), AUO (AUOTY), American Water Works (AWK), The RMR Group (RMR) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
3/20/2025
Today
5/03/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:ASMB
Employees
100
Year Founded
2005

Price Target and Rating

Average Stock Price Target
$33.00
High Stock Price Target
$35.00
Low Stock Price Target
$31.00
Potential Upside/Downside
+132.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-61,230,000.00
Net Margins
-144.05%
Pretax Margin
-142.50%

Debt

Sales & Book Value

Annual Sales
$28.52 million
Price / Cash Flow
N/A
Book Value
$7.50 per share
Price / Book
1.89

Miscellaneous

Free Float
6,032,000
Market Cap
$108.31 million
Optionable
Optionable
Beta
0.65

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ASMB) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners